Gilead: FDA Places Partial Clinical Hold On Studies Evaluating Magrolimab - Azacitidine Combination
26/1 02:45
(RTTNews) - Gilead Sciences Inc. (GILD) said Tuesday that the U.S. Food and Drug Administration has placed a partial clinical hold on studies evaluating the combination of magrolimab plus azacitidine due to an apparent imbalance in investigator-reported suspected unexpected serio...